Cargando…
The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis
Autores principales: | Ungar, Benjamin, Lavin, Leore, Golant, Alexandra K., Gontzes, Alyssa, David, Eden, Estrada, Yeriel D., Singer, Giselle K., Pavel, Ana B., Guttman-Yassky, Emma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956356/ https://www.ncbi.nlm.nih.gov/pubmed/35346880 http://dx.doi.org/10.1016/j.anai.2022.03.019 |
Ejemplares similares
-
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
por: Ungar, Benjamin, et al.
Publicado: (2022) -
Impact of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the atopic dermatitis serum proteome
por: Kim, Madeline, et al.
Publicado: (2023) -
Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers
por: He, Helen, et al.
Publicado: (2020) -
Dupilumab for atopic dermatitis
Publicado: (2019) -
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)